Helping MindMed Succeed

MindMed Zone

MindMed ZoneMindMed ZoneMindMed Zone

MindMed Zone

MindMed ZoneMindMed ZoneMindMed Zone
  • Home
  • Activist Letters
  • Press
  • Signup
  • More
    • Home
    • Activist Letters
    • Press
    • Signup
  • Home
  • Activist Letters
  • Press
  • Signup

FCM's Activist Letters

FCM's Value Enhancement Plan

In this letter dated August 11, 2022, to Chairman of the Board Carol Vallone, FCM proposed its value enhancement plan to drastically cut spending, target MindMed's focus on MM-120 and MM-110, cut executive spending, among a litany of other strategic enhancements to unlock significant value for MindMed shareholders.  

Read the Value Enhancement Plan

FCM Poses Question of Ceruvia Agreement to MindMed Board

In this letter dated October 21, 2022, to Chairman of the Board Carol Vallone, FCM put forth a slew of documents and posed serious questions to the Board regarding the alleged Ceruvia deal, a conflict of interest that MindMed's Chief of Staff Nico Forte may have, and questions and documents casting aspersions on Robert Barrow's qualification. 

Read FCM's Letter Regarding Ceruvia Agreement Et AL

FCM Opposes MindMed's Destructive Dilutive Financing

In this letter dated September 28, 2022, to Chairman of the Board Carol Vallone, FCM strenuously opposes MindMed's public offering of shares and pledges to hold MindMed Board and executives accountability through shareholder activist campaign. 

Read FCM's Letter Opposing MindMed's Public Offering

FCM Demands Investigation, Termination of CEO

In this letter dated November 3, 2022, to Chairman of the Board Carole Vallone, FCM demands, for reasons expounded upon in the letter, the termination of CEO Robert Barrow, Chief of Staff Nico Forte, and Board Member Brigid Makes. FCM also demands that MindMed investigate the creation of clone website Medihuasca.

Read FCM's Demand For Termination and Investigation

FCM Responds to MindMed CEO Robert Barrow's Interview

In this letter to shareholders dated October 13, 2022, FCM demonstrates the shortcomings in CEO Robert Barrow responses to critical questions regarding MindMed's intellectual property and serious issues relating to historic co-mingling of MindMed's employees with rival Ceruvia. FCM provided a slew of documents as exhibits to this letter.

Read FCM's Analysis of Barrow's Interview

FCM's Jake Freeman Challenges MindMed's CEO to Debate

In this letter dated October 3, 2022, FCM's Jake Freeman challenged MindMed's CEO Robert Barrow to a debate on the following issues: intellectual property, shareholder dilution, and conflicts of interest. Mr. Freeman proposed that the debate would be integral to creating intellectual synthesis on the issues.

Read In Re Barrow et Freeman Debate

FCM Informs MindMed of Financial Misstatements, Questions Internal Controls

In this letter dated November 14, 2022, FCM informs MindMed of a financial misstatement and questions whether MindMed has sufficient internal controls. Additionally, the letter expresses FCM's opinion on management receiving golden parachusets at this critical juncture.

Read In Re MindMed Misstatements

Copyright © 2022 FCM MM HOLDINGS, LLC - All Rights Reserved.

  • Disclosure
  • Disclosures